RxDoctor Payments Data

Natalya Rodionova

Family Medicine · Bronx, NYNPI 1679654768

Payments from drug & device makers

$29,682in general payments, 2019–2025

Across 1,883 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$4K
  • GSK$3K
  • AstraZeneca$2K
  • Amgen$2K
  • Lilly USA, LLC$2K
  • plus $11K from 53 others

What the payments were for

  • Food & beverage$29,38999%
  • Education$2941%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)523$7,332
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC251$4,119
GSK132$2,580
AstraZeneca95$1,845
Amgen(2 entities)114$1,641
Lilly USA, LLC96$1,551
Scilex Pharmaceuticals Inc.193$1,376
Merck60$1,146
Boehringer Ingelheim30$712
Novo Nordisk30$596
Vanda Pharmaceuticals Inc.25$570
Hikma Pharmaceuticals USA35$568
Sanofi-aventis U.S. LLC32$555
Pfizer30$485
Novartis34$442
Kowa Pharmaceuticals America, Inc.29$430
Cumberland Pharmaceuticals, Inc.13$423
Amarin Pharma, Inc.21$376
Takeda Pharmaceuticals U.S.A., Inc.13$246
Ironwood Pharmaceuticals, Inc11$236
Otsuka America Pharmaceutical, Inc.10$236
Shield Therapeutics Inc10$199
Johnson & Johnson(2 entities)8$165
Alkermes, Inc.5$121
Bayer5$114
Nestle Healthcare Nutrition Inc.6$111
Ardelyx, Inc.6$110
Astellas Pharma US Inc1$94
Exact Sciences3$86
Biohaven Pharmaceuticals, Inc.4$79
Gilead4$74
Aimmune Therapeutics, Inc.4$72
E.r. Squibb & Sons, L.L.C.3$71
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$70
Axsome Therapeutics, Inc.3$66
Lundbeck LLC3$65
Sanofi2$59
Phathom Pharmaceuticals, Inc.3$54
Lexicon Pharmaceuticals, Inc.3$50
Corcept Therapeutics2$48
Viiv Healthcare Company2$48
Esperion Therapeutics, Inc.3$46
Xeris Pharmaceuticals, Inc.2$46
Amphastar Pharmaceuticals, Inc.2$42
Verrica Pharmaceuticals Inc.2$37
Teva Pharmaceuticals USA, Inc.2$34
Circassia Inc.2$29
Radius Health, Inc.1$26
Mylan Specialty L.p.1$25
Sanofi Pasteur Inc.1$22
Biohaven Pharmaceutical Holding Company Ltd.1$21
Mannkind Corporation1$21
Avanir Pharmaceuticals, Inc.1$20
Phadia US Inc.1$18
Dexcom, Inc.1$18
Redhill Biopharma Inc.1$17
BD1$16
Impel Pharmaceuticals Inc.1$12
Althera Pharmaceuticals LLC1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,682 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$52,638
Medicare patients
78
Services billed
1,215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium455$249,095
Lactulose203$212,073
ZenpepLipase/Protease/Amylase126$201,260
OzempicSemaglutide136$183,509
Trelegy ElliptaFluticasone/Umeclidin/Vilanter142$136,002
JanuviaSitagliptin Phosphate122$125,592
FarxigaDapagliflozin Propanediol139$124,525
LinzessLinaclotide130$123,214
EliquisApixaban112$106,988
XareltoRivaroxaban112$105,344
CreonLipase/Protease/Amylase65$99,541
EntrestoSacubitril/Valsartan88$97,039
Clemastine Fumarate15$90,827
VraylarCariprazine Hcl31$68,291
ProliaDenosumab37$59,867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Vraylar, Namzaric, Ubrelvy$7,332$375,668300 claims
Novo NordiskOzempic, Rybelsus$596$215,184154 claims
Aimmune Therapeutics, Inc.Zenpep$72$201,260126 claims
MerckJanuvia, Verquvo, Janumet$1,146$194,984177 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,845$173,400189 claims
PfizerEliquis, Nurtec Odt$485$140,792136 claims
GSKTrelegy Ellipta$2,580$136,002142 claims
Johnson & JohnsonXarelto$165$105,344112 claims
NovartisEntresto$442$97,03988 claims
Boehringer IngelheimJardiance, Tradjenta$712$72,41862 claims
AmgenProlia$1,641$59,86737 claims
Lilly USA, LLCMounjaro, Trulicity$1,551$51,22642 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.

Other family medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →